Navigation Links
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone)
Date:9/17/2010

SILVER SPRING, Md., Sept. 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The preliminary results are based on five-year data from an ongoing, 10-year observational study by the manufacturer, Takeda Pharmaceuticals North America Inc., San Diego. These early results showed no overall association between Actos exposure and risk of bladder cancer. However, there was an increased risk of bladder cancer in patients with the longest exposure to Actos and in those with the highest cumulative dose of the drug.

At this time, the FDA's review is ongoing. The agency has not concluded that Actos increases the risk of bladder cancer.

Actos (pioglitazone) is used to control blood sugar in patients with type 2 diabetes mellitus. It is in the class of drugs known as peroxisome proliferator-activated receptor (PPAR) agonists. The only other drug in this class is Avandia (rosiglitazone).  The FDA has no clinical information associating Avandia with bladder cancer in patients receiving that drug.  

Patients should talk to their health care professional if they have concerns about Actos. They should not stop taking the drug unless told to do so by their health care professional.

For more information

Ongoing Safety Review of Actos (pioglitazone) and Increased Risk of Bladder Cancer

http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm


'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Reviewing Biomoda Submission for Cancer Screening Study
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
9. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Headquartered in ... a diversified company comprised of several specialized partners focused ... and the proven expertise of its team of professionals ... WholeHealth Products, line of more than 10 professional diagnostic ... its more than 8 retail consumer tests is proud ...
(Date:9/30/2014)... , Sept. 30, 2014  Synapse Biomedical Inc. ( ... enrollment of the post-approval study of its NeuRx ... needed to meet the FDA enrollment requirement was ... of schedule.  The NeuRx DPS®, which is the ... for ALS patients, is a humanitarian device that ...
(Date:9/30/2014)... 30, 2014 Summary This report ... pharmaceutical companies regarding their Information & Communications Technology ... companies currently allocate their ICT budgets across the ... IT services, communications, and consulting. Key ... companies highlights that X% of respondents anticipate an ...
Breaking Medicine Technology:WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 2ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 3
... 7, 2011 Healthmark Industries was honored with two ... Healthcare Central Service Personnel (MSHCSP). At last ... presented with the Lifetime Honorary Achievement Award for his ... The same night Healthmark was also awarded ...
... Among the first healthcare providers to have money in ... health record (EHR) incentive program -- are two Texas ... Canadian, Texas. Both Stamford and Hemphill quickly ... meaningful use to be among the initial 37 hospitals ...
Cached Medicine Technology:Two Texas Hospitals Leverage Prognosis EHR to Meet Meaningful Use Requirements and Receive ARRA Incentive Funds 2
(Date:9/30/2014)... Hospice & Palliative Care of ... gala, honoring three outstanding individuals for their commitment ... provide extraordinary and dignified comfort, care and compassion ... life-limiting illness. , The event was held at ... recognized William (Bill) J. McGuinness, Director of Tiffany ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
(Date:9/30/2014)... WASHINGTON (Sept. 30, 2014) Levothyroxine is considered the ... and a new review of therapies for the condition ... not altered that assessment, say a team of investigators.,1Their ... journal Thyroid , finds insufficient consistent data exist ... whether generic, or sold under various trade names, such ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... September 30, 2014 Market Research ... is a professional and in-depth market survey on ... reviews the basic information of Cialis including its ... explores global and China’s top manufacturers of Cialis ... market share etc. , The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... , TUESDAY, March 1 (HealthDay News) -- A ... hospitals for sepsis -- a potentially life-threatening bacterial infection in ... those treated at other hospitals. Researchers analyzed data from ... sepsis between June 2004 and June 2006. In total, there ...
... over time been able to show that medicine designed ... serious diseases such as cancer. However, now research also ... part in the drug delivery process. "Researchers ... of viruses. The nanoparticles are effective for drug delivery ...
... ATLANTA March 1, 2011 A new report from ... the 141,000 cases and 49,000 deaths from colorectal cancer ... prevented by increasing the use of established screening tests ... The report, Colorectal Cancer Facts & Figures 2011-2013, released ...
... Invasive plant species have long had a reputation as being ... Stan Harpole, assistant professor of ecology, evolution and organismal biology ... of more than 70 researchers working at 65 sites worldwide ... it is true that problematic invasive species often spread widely ...
... Los Angeles, CA (February 28, 2011) Eating more tomatoes ... the risk of conditions such as cancer, osteoporosis and ... American Journal of Lifestyle Medicine , (published by SAGE). ... tomatoes and tomato products than any others. Researchers Britt ...
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
Cached Medicine News:Health News:Hospital Spending Doesn't Affect Sepsis Survival Rates 2Health News:Research provides new findings on drug delivery with nanoparticles 2Health News:New report says large proportion of colorectal cancer deaths could be prevented 2Health News:Global ISU study: Invasive species widespread, but not more than at home range 2Health News:Health benefits of eating tomatoes emerge 2Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: